Category Archive for "Research"

Home »

Quick Thoughts – Early iBeacon Trials are Encouraging for Apple

Digital wallet-provider LevelUp reports that mobile payments volume increased 22% over 30 days at the 50 merchants where it installed iBeacon. As discussed in our May 30th note, “Apple vs. Banks in Mobile Payments: Update”, the focus of iBeacon is

Read More

ADS, AXP and JPM: The Bank Edge over Online Advertising and Payments Platforms

There is a secular shift in advertising from generic brand advertising on broadcast channels to data-enabled direct marketing on digital channels. Our colleague, Paul Sagawa, reported on the shift in a research note of June 9th titled “The Revolution in

Read More

Quick Thoughts: Priceline buys OpenTable, puts International and Mobile Growth on Steroids

–          PCLN’s cash acquisition of OPEN for $2.6B should deliver clear synergies for expanding OPEN into international markets and bundling mobile services with other PCLN properties –          PCLN has the resources to stimulate growth and could also lever OPEN’s reservation

Read More

Quick Thoughts: JPM – Cyclical Improvement in NIM and FICC will Lever over Flat-to-Down Expenses for a 2015 EPS Beat

JPM’s economic model is to sustain a tangible ROE of 15-16% despite lifting the CET1 ratio (to 10-10.5% from the current 9.6%) by levering higher net interest income over flat-to-down expenses (for a 55% efficiency ratio vs. 59% in 2013);

Read More

And the Winner is…TSN’s Bankers?

In news that appears to put an end to the saga of Hillshire Farms (HSH), TSN has emerged as the “winning” bidder with a $63 per share offer. o   This implies a 15.7x multiple of EV to TTM EBITDA, rarefied

Read More

The Shift from Signature Debit and Prospect for a Bank-Owned PIN Debit Network

The debit business in the US is unsustainable. Durbin-regulated banks are losing money on signature debit as the swipe fee has fallen to 24 cents/transaction (from a pre-Durbin 59 cents) vs. Fed estimates for fraud and processing costs at 30

Read More

Large Pharma’s ‘Established’ & ‘Growth’ NEWCOs: A Solomonic Path to More Efficient R&D?

We divided the large cap pharmaceutical companies into ‘established’ and ‘growth’ NEWCOs; we then compared the combined value of the ‘established’ and ‘growth’ NEWCOs to the legacy parent companies, and found no compelling evidence to believe the combined NEWCO values

Read More

June 9, 2014 – TMT: The Advertising Revolution Will NOT Be Televised

TMT: The Advertising Revolution Will NOT Be Televised Since the 2010 recovery, US TV ad spending, adjusted for Olympic/campaign bumps in 2010 and 2012, has been decelerating. The price of a primetime spot has steadily declined, offset by increasing the

Read More

Impact of European Monetary Policy on Bank Margins in the US

European monetary policy matters to bank net interest margins in the US because the risk of disinflation has collapsed European bond yields (to 1.6% on the 10-year from 2.2% at end-2013) dragging down US Treasury yields (to 2.6% on the

Read More

SSR Health New Product Approval Portfolios & Supporting Data Update

Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the year or so before and after regulatory actions (‘PDUFA’ dates) on major new products, with a large portion of total risks being concentrated in the days

Read More
test